BioSpace News Archive

Rostock International Parkinson’s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment Significant milestone of 10,000 participants reached With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed

Curie Oncology expands Caris’ collaborative network of oncology institutions focused on research into personalized therapies through precision medicine

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the fourth quarter and year ended December 31, 2020.

DarioHealth Corp., a pioneer in the global digital therapeutics market, reported financial results for the fourth quarter and full year 2020 and provided a corporate and commercial update.

Titan Medical Inc., a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced a corporate update in conjunction with its presentation at the H.C. Wainwright Global Life Sciences Conference.

NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported on the strong effectiveness of its two COVID-19 clinical drug candidates in an animal model of coronavirus infection.

Ra Medical Systems, Inc . (NYSE: RMED) announces that it will report 2020 fourth quarter and full year financial results and provide a business update after market close on Tuesday, March 16, 2021. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

Kamada Ltd., a plasma-derived biopharmaceutical company, announced that Amir London, Chief Executive Officer, will present a corporate overview at the inaugural Jefferies Virtual Global Plasma Summit, being held on March 11, 2021.

-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyperuricemia and gout -- -- Management team strengthened with addition of David Clark, M.D., M.R.C.P as Chief Medical Officer and Richard Katz, M.D. as Chief Financial Officer -- NEWTON, Mass., March 09, 2021

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, reported its financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of its 2020 and 2021 year-to-date operational highlights.